Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus PHOSLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus PHOSLO.
AURYXIA vs PHOSLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable; minimal systemic absorption, local gastrointestinal action
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Category C
Category C
Phosphate Binder
Phosphate Binder